Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/full |
id |
doaj-5541401c5b994dd3b6167a706c8a49d4 |
---|---|
record_format |
Article |
spelling |
doaj-5541401c5b994dd3b6167a706c8a49d42021-09-27T05:14:30ZengFrontiers Media S.A.Frontiers in Public Health2296-25652021-09-01910.3389/fpubh.2021.732787732787Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 InfectionJulia Schiffner0Julia Schiffner1Julia Schiffner2Insa Backhaus3Jens Rimmele4Sören Schulz5Till Möhlenkamp6Julia Maria Klemens7Dorinja Zapf8Werner Solbach9Werner Solbach10Werner Solbach11Alexander Mischnik12Center for Infection and Inflammation Research, University of Luebeck, Luebeck, GermanyGerman Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyMedical Faculty, Centre for Health and Society, University Hospital, Institute of Medical Sociology, Heinrich-Heine-University, Düsseldorf, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, GermanyInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, GermanyCenter for Infection and Inflammation Research, University of Luebeck, Luebeck, GermanyGerman Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyCharacterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/fullCOVID-19SARS-CoV-2immunoglobulinIgGseroprevalenceinterferon-gamma release assay |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julia Schiffner Julia Schiffner Julia Schiffner Insa Backhaus Jens Rimmele Sören Schulz Till Möhlenkamp Julia Maria Klemens Dorinja Zapf Werner Solbach Werner Solbach Werner Solbach Alexander Mischnik |
spellingShingle |
Julia Schiffner Julia Schiffner Julia Schiffner Insa Backhaus Jens Rimmele Sören Schulz Till Möhlenkamp Julia Maria Klemens Dorinja Zapf Werner Solbach Werner Solbach Werner Solbach Alexander Mischnik Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection Frontiers in Public Health COVID-19 SARS-CoV-2 immunoglobulin IgG seroprevalence interferon-gamma release assay |
author_facet |
Julia Schiffner Julia Schiffner Julia Schiffner Insa Backhaus Jens Rimmele Sören Schulz Till Möhlenkamp Julia Maria Klemens Dorinja Zapf Werner Solbach Werner Solbach Werner Solbach Alexander Mischnik |
author_sort |
Julia Schiffner |
title |
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection |
title_short |
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection |
title_full |
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection |
title_fullStr |
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection |
title_full_unstemmed |
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection |
title_sort |
long-term course of humoral and cellular immune responses in outpatients after sars-cov-2 infection |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Public Health |
issn |
2296-2565 |
publishDate |
2021-09-01 |
description |
Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status. |
topic |
COVID-19 SARS-CoV-2 immunoglobulin IgG seroprevalence interferon-gamma release assay |
url |
https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/full |
work_keys_str_mv |
AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT insabackhaus longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT jensrimmele longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT sorenschulz longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT tillmohlenkamp longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT juliamariaklemens longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT dorinjazapf longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection AT alexandermischnik longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection |
_version_ |
1716867159141908480 |